AXS26_DigitalGuide_Final pages - Flipbook - Page 36
More than a pen—
A springboard to everyday
bleed protection1,a
The 昀椀rst TFPI antagonist in a pre昀椀lled, subcutaneous
pen to prevent or reduce the frequency of bleeding
episodes in adult and pediatric patients 12 years of
age and older who have hemophilia B or A, with or
without inhibitors1
a
Adherence to daily dosing of Alhemo® is important to maintain
protection against bleeding.1
Actor portrayal.
Learn more
about Alhemo®
Needles sold separately and may require a prescription in some states.
TFPI=tissue factor pathway inhibitor.
Indications and Usage
®
Alhemo (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is
indicated for routine prophylaxis to prevent or reduce the frequency of
bleeding episodes in adult and pediatric patients 12 years of age and
older with hemophilia A or B with or without Factor VIII or IX inhibitors.
Important Safety Information
Contraindications
• Alhemo® is contraindicated in patients with a history of known serious
hypersensitivity to Alhemo® or its ingredients
Warnings and Precautions
• Thromboembolic Events (TEs): Venous and arterial TEs were reported
in 1.9% of patients (6/320) who also had multiple risk factors, including
the use of high doses or prolonged treatment with factor product or
bypassing agent (2 of 6 patients). Risk factors for TEs may also include
conditions in which tissue factor is overexpressed (eg, atherosclerotic
disease, crush injury, cancer, disseminated intravascular coagulation,
thrombotic microangiopathy, or septicemia). Inform patients about
and monitor them for signs and symptoms of TEs. In case of suspicion
of TEs, discontinue Alhemo® and initiate further investigations and
management strategies
• Hypersensitivity Reactions: Alhemo® is contraindicated in patients
with a history of known serious hypersensitivity to Alhemo® or its
ingredients. Hypersensitivity reactions, including erythema, rash,
pruritus, and abdominal pain, have occurred in patients treated with
Alhemo®. One patient (
